Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00078-0715-02 00078-0715 Alpelisib PIQRAY Chemotherapy Enzyme Inhibitor PI3K Oral May 24, 2019 In Use
62856-0601-22 62856-0601 Alitretinoin Panretin 60.0 mg/60g Hormonal Therapy Immunomodulator Retinoic Acid Derivative Topical Feb 3, 2009 Oct 31, 2021 No Longer Used
59212-0601-22 59212-0601 alitretinoin PANRETIN 60.0 mg/60g Hormonal Therapy Immunomodulator Retinoic Acid Derivative Topical Sep 10, 2019 In Use
58468-0357-01 58468-0357 Alemtuzumab Campath 30.0 mg/mL Immunotherapy Monoclonal Antibody CD52 Intravenous Nov 30, 2009 In Use
58468-0357-03 58468-0357 Alemtuzumab Campath 30.0 mg/mL Immunotherapy Monoclonal Antibody CD52 Intravenous Nov 30, 2009 In Use
50242-0130-86 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Oct 10, 2017 In Use
50242-0130-01 50242-0130 ALECTINIB HYDROCHLORIDE Alecensa 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor ALK Oral Dec 11, 2015 In Use
00078-0495-61 00078-0495 Aldesleukin Proleukin 1.1 mg/mL Immunotherapy Cytokine Interleukin-2 Intravenous May 6, 1992 Jan 1, 2017 No Longer Used
65483-0116-07 65483-0116 Aldesleukin Proleukin 1.1 mg/mL Immunotherapy Cytokine Interleukin-2 Intravenous May 5, 1992 In Use
00597-0138-95 00597-0138 Afatinib Gilotrif 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 8, 2013 In Use
00597-0137-30 00597-0137 Afatinib Gilotrif 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 9, 2013 In Use
00597-0137-90 00597-0137 Afatinib Gilotrif 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct 1, 2018 In Use
00597-0138-30 00597-0138 Afatinib Gilotrif 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 8, 2013 In Use
00597-0141-30 00597-0141 Afatinib Gilotrif 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 13, 2013 In Use
83205-0001-02 83205-0001 Afamitresgene autoleucel TECELRA 10000000000.0 1/1 Immunotherapy T Cell Receptor (TCR) MAGE-A4 Intravenous Aug 2, 2024 In Use
50242-0088-01 50242-0088 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb 22, 2013 In Use
50242-0087-01 50242-0087 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb 22, 2013 In Use
80739-0812-12 80739-0812 Adagrasib KRAZATI 200.0 mg/1 Immunotherapy RAS Inhibitor KRAS G12C Oral Dec 12, 2022 In Use
80739-0812-18 80739-0812 Adagrasib KRAZATI 200.0 mg/1 Immunotherapy RAS Inhibitor KRAS G12C Oral Dec 12, 2022 In Use
00310-0512-60 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Oct 31, 2017 In Use
00310-3512-95 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug 4, 2022 In Use
00310-0512-28 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Apr 1, 2018 Jul 31, 2021 In Use
00310-0512-95 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Apr 1, 2020 Jul 31, 2025 In Use
00310-3512-60 00310-3512 Acalabrutinib CALQUENCE 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Aug 4, 2022 In Use
69238-1754-06 69238-1754 ABIRATERONE ABIRATERONE ACETATE 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Jan 7, 2019 In Use

Found 11120 results — Export these results